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Objectives. This study was designed to determine the frequency
of 22q11 deletions in a large, prospectively ascertained sample of
patients with conotruncal defects and to evaluate the deletion
frequency when additional cardiac findings are also considered.
Background. Chromosome 22q11 deletions are present in the
majority of patients with DiGeorge, velocardiofacial and
conotruncal anomaly face syndromes in which conotruncal defects
are a cardinal feature. Previous studies suggest that a substantial
number of patients with congenital heart disease have a 22q11
deletion.
Methods. Two hundred fifty-one patients with conotruncal
defects were prospectively enrolled into the study and screened for
the presence of a 22q11 deletion.
Results. Deletions were found in 50.0% with interrupted aortic
arch (IAA), 34.5% of patients with truncus arteriosus (TA), and
15.9% with tetralogy of Fallot (TOF). Two of 6 patients with a
posterior malalignment type ventricular septal defect (PMVSD)
and only 1 of 20 patients with double outlet right ventricle were
found to have a 22q11 deletion. None of the 45 patients with
transposition of the great arteries had a deletion. The frequency of
22q11 deletions was higher in patients with anomalies of the
pulmonary arteries, aortic arch or its major branches as com-
pared to patients with a normal left aortic arch regardless of
intracardiac anatomy.
Conclusions. A substantial proportion of patients with IAA, TA,
TOF and PMVSD have a deletion of chromosome 22q11. Deletions
are more common in patients with aortic arch or vessel anomalies.
These results begin to define guidelines for deletion screening of
patients with conotruncal defects.
(J Am Coll Cardiol 1998;32:492–8)
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Chromosome 22q11 deletions are present in the majority of
patients with DiGeorge (DGS), velocardiofacial (VCFS) and
conotruncal anomaly face (CTAFS) syndromes indicating that
these conditions share a common genetic etiology (1–5). The
major features of these syndromes include congenital heart
disease, aplasia or hypoplasia of the thymus and/or parathyroid
glands, palatal abnormalities, speech and learning disabilities
and facial dysmorphia (6,7). The cardiac defects commonly
seen in these disorders derive from the conotruncus, the
embryonic aortic arches and the ventricular septum. In the
original clinical description of these syndromes, interrupted
aortic arch type B (IAA), truncus arteriosus (TA), and tetral-
ogy of Fallot (TOF) comprised approximately 75% of the
cardiac lesions found in DGS, whereas TOF, ventricular septal
defects and right aortic arch were the most frequently reported
defects in VCFS (8,9). All of the above lesions were reported
in association with CTAFS (5).
Previous studies suggest that a substantial number of pa-
tients with conotruncal defects have a 22q11 deletion (10–15).
However, these studies were limited by their relatively small
sample size. The present study was designed to determine the
frequency of the 22q11 deletion in a large, prospectively
ascertained sample of patients with conotruncal defects on the
cardiology service at a tertiary care center. Both primary
diagnosis and associated cardiac anatomy were analyzed with
respect to the deletion status. These results begin to provide
cardiologists with guidelines for genetic testing and further
evaluation of patients with conotruncal defects.
Methods
Study population. Patients with one of the following car-
diac lesions were eligible for the study: IAA (type A, B or C),
TA, TOF, transposition of the great arteries (TGA), double
outlet right or left ventricle (DORV, DOLV respectively) and
posterior malalignment type ventricular septal defect without
interruption of the aortic arch (PMVSD). Subjects were re-
cruited solely on the basis of cardiac findings. Extracardiac
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features were not considered in the recruitment process.
Patients with IAA, TA and TOF were included in this study
because, historically, these are the most common cardiac
defects seen in DGS (8). Patients with PMVSD, TGA, DORV
and DOLV were also studied because these lesions may be
embryologically and genetically related to the defects seen in
DGS. For the purpose of this study, DORV is defined only by
the lack of fibrous continuity between the mitral and aortic
valves in conjunction with an aorta arising more than 50% over
the right ventricle, and therefore includes a wide spectrum of
defects. In contrast, TOF is defined as the presence of an
anterior malalignment type VSD with deficient subpulmonic
conus and fibrous continuity between the mitral and aortic
valves. PMVSD is defined as the posterior malalignment of the
infundibular septum into the subaortic region and can be
associated with aortic arch hypoplasia or coarctation but
without complete interruption.
Patients with perimembranous VSD and isolated arch
anomalies, which have been reported in association with
VCFS, were not included as part of the present study. Patients
with aneuploidy, such as trisomy 21, translocations or hetero-
taxy syndrome were excluded.
The majority of the study patients was identified prospec-
tively from the elective cardiac catheterization or operative
procedure schedules, or as newly diagnosed patients admitted
to The Children’s Hospital of Philadelphia. The parents were
approached prior to the procedure or while in the hospital, and
were invited to participate in the research protocol. Recruit-
ment at the time of a hospitalization or invasive procedure
allowed for painless acquisition of a blood sample from
indwelling central lines and increased the parental willingness
to participate. Furthermore, the procedure schedules note the
cardiac diagnoses but make no mention of extracardiac diag-
noses, and thus help to minimize selection biases. A few older
patients who were willing to undergo a venipuncture were
recruited from the outpatient setting, but this patient pool was
not systematically approached given the reluctance of most
parents to allow their children to undergo venipuncture for
research purposes. Given that all patients with one of the
eligible cardiac diagnoses undergo surgery, the recruitment of
hospitalized patients is unlikely to introduce significant bias in
our sample. We attempted to recruit consecutive patients with
these diagnoses, although the number of eligible patients often
exceeded our resources. Thus, some patients were missed due
to time and personnel constraints. At no time did the presence
or absence of extracardiac features knowingly influence the
decision to approach a family. A small number of patients (n 5
26) were enrolled by one of our collaborators (BFC) following
the same protocol. The study protocol was approved by the
Institutional Review Board for the Protection of Human
Subjects at The Children’s Hospital of Philadelphia. Written
consent for each subject was obtained before enrollment into
the study.
Two hundred fifty-one patients, including 39 patients pre-
viously reported, were prospectively enrolled in the study from
November 1991 to June 1996 based on their cardiac diagnosis
alone (10,15). One hundred thirty-five (53.8%) of the patients
were male, 109 (43.4%) were female and 7 (2.8%) were
unknown. There were 168 (66.9%) whites, 45 (17.9%) African-
Americans, 9 (3.6%) Hispanics, 4 (1.6%) Asians, 2 (0.8%)
Native-American Indians, and 23 (9.2%) of other or unknown
race.
Cardiac evaluation and diagnosis. Cardiac anatomy was
diagnosed by echocardiography, cardiac catheterization or
cardiac magnetic resonance imaging studies. When available,
the surgical operative note was reviewed (213/251 cases overall
and 6/6 cases with PMVSD). The data were reviewed by two
cardiologists (E.G., B.J.C.) and entered into an Ingres data-
base. Only those patients with complete anatomic description
of their cardiac defects were included in this study. The
primary diagnoses included IAA, TA, TOF, PMVSD, DORV,
DOLV or TGA. All associated cardiac features were entered
as secondary diagnoses including cardiac segments, side of the
aortic arch, aortic arch anomalies, pulmonary artery anoma-
lies, presence of aortopulmonary collaterals and systemic or
pulmonic venous anomalies.
Deletion analysis. Deletion status was determined in the
initial 17 patients by quantitative Southern blot hybridization
as previously reported (10). The remaining patients were
evaluated for the presence of a deletion by fluorescence in situ
hybridization (FISH). Metaphase chromosomes from either
peripheral blood lymphocytes, lymphoblastoid cell lines, cul-
tured amniocytes or chorionic villi were cohybridized with the
cosmid probe N25(D22S75) from within the DiGeorge chro-
mosomal region (DGCR) and a control probe [cos 82 or
pH17(D22S39) as supplied by Oncor] mapping to the distal
long arm of chromosome 22 (Fig. 1). A cosmid probe for locus
D22S66 was used to evaluate patients with TGA for smaller
deletions within the DGCR.
Statistical methods. The frequency of the chromosome
22q11 deletion was calculated for the total sample of patients,
as well as for the selected subgroups of patients. Differences in
the frequency of this deletion, between subgroups of patients
defined by either primary or secondary cardiac diagnoses, were
compared by chi-square analysis, Fisher’s exact test or the odds
ratio.
Multiple logistic regression analyses were used to deter-
Abbreviations and Acronyms
CTAFS 5 conotruncal anomaly face syndrome
DGCR 5 DiGeorge chromosomal region
DGS 5 DiGeorge syndrome
DOLV 5 double outlet left ventricle
DORV 5 double outlet right ventricle
FISH 5 fluorescence in situ hybridization
IAA 5 interrupted aortic arch
PMVSD 5 posterior malalignment type ventricular septal defect
TGA 5 transposition of the great arteries
TA 5 truncus arteriosus
TOF 5 tetralogy of Fallot
VCFS 5 velocardiofacial syndrome
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mine whether deletion status (that is, deleted versus non-
deleted) is independently related to both the primary and
secondary cardiac diagnoses. These analyses were restricted to
data from individuals with one of four primary diagnoses (IAA,
TA, TOF and PMVSD) and the secondary cardiac diagnoses
were grouped into four, non-overlapping categories: normal
left aortic arch (i.e., no secondary cardiac anomaly), right
aortic arch with mirror image branching, left aortic arch with at
least one vessel abnormality and right aortic arch with at least
one vessel abnormality.
Three logistic regression models were fit to the data. The
full model (model 1) included three dummy variables that
defined the four primary diagnoses, and three dummy variables
that defined the four secondary diagnoses. Two reduced
models, one including only the dummy variables for the
primary diagnoses (model 2), and the other including only the
dummy variables for the secondary diagnoses (model 3) were
also fit to the data. The fit of each reduced model, relative to
that of the full model, was evaluated by use of the likelihood
ratio test (that is, twice the difference between the log likeli-
hood of the full and reduced model). This test is distributed
approximately as a chi-square test, with degrees of freedom
determined by the difference in the number of parameters
estimated by the two models.
Comparison of the full model (model 1) with model 2 tests
whether secondary cardiac diagnoses are significantly related
to deletion status, independent of the effects of the primary
diagnoses. In contrast, comparison of the full model with
model 3 tests whether primary cardiac diagnoses are signifi-
cantly related to deletion status, independent of the effects of
the secondary diagnosis.
Statistical analyses were conducted using SAS version 6.10
and Epi Info version 6.03 (16,17).
Results
Deletion frequency by primary cardiac diagnosis. A total
of 251 patients with one of seven conotruncal defects were
enrolled in the study and evaluated for a 22q11 deletion at
locus D22S75 (N25) (Fig. 1). Forty-five patients (17.9%, 95%
C.I. 13.2 to 22.7) were found to have a deletion. The propor-
tion of patients with a 22q11 deletion varied with the primary
cardiac diagnosis (Table 1). Deletions were most common in
patients with one of the three cardiac defects seen most
commonly in DGS including 50.0% (12/24) of patients with
IAA, 34.5% (10/29) of patients with TA, and 15.9% (20/126) of
patients with TOF, as well as 33.3% (2/6) of patients with
PMVSD. Deletions were only found in patients with IAA type
B, although only three patients with IAA type A were evalu-
ated. There was no statistical difference in the deletion fre-
quency between patients with TOF/pulmonary atresia, TOF/
pulmonary stenosis or TOF/absent pulmonary valve (Fisher’s
exact test, p 5 0.55). Only one of 20 patients with DORV had
a 22q11 deletion.
Deletions at locus D22S75 (N25) were not detected in 45
patients with either d- or l-TGA, with or without a ventricu-
loseptal defect (Table 1). To assess whether some of these
patients might have a smaller deletion distal to D22S75, 21 of
the 45 patients were studied by FISH using a probe for locus
D22S66, which maps approximately 550 kb distal to D22S75
(Fig. 1). None of the 21 TGA patients studied was deleted at
locus D22S66.
Table 1. Frequency of the 22q11 Deletion in Patients With a
Conotruncal Heart Defect
Primary Diagnosis Total
No.
Deleted
% Deleted
(95% CI)*
Interrupted aortic arch 24 12 50.0 (30.0–70.0)
Type A 3 0 0.00
Type B 21 12 57.1 (36.0–78.3)
Truncus arteriosus 29 10 34.5 (17.2–51.8)
Type A1 16 4 25.0 (3.8–46.2)
Type A2 6 2 33.3 (0.0–71.1)
Type A3 1 1 100.0
Type A4 6 3 50.0 (10.0–90.0)
Posterior malalignment type 6 2 33.3 (0.00–71.0)
Ventricular septal defect
with coarctation 4 1 25.5 (0.00–67.4)
Tetralogy of Fallot 126 20 15.9 (9.5–22.2)
Double outlet right ventricle 20 1 5.0 (0.00–14.6)
Double outlet left ventricle 1 0 0.00
Transposition of great arteries 45 0 0.00
S,D,D† 39 0 0.00
S,L,L‡ 6 0 0.00
Total 251 45 17.9 (13.2–22.7)
*95% CI 5 p 6 1.96√p(1-p)/n, where p 5 proportion of cases with a deletion
and n 5 the total number of cases. †12 patients with ventricular septal defect. ‡4
patients with ventricular septal defect.
Figure 1. Idiogram of chromosome 22 illustrating the commonly
deleted region (DGCR, hatched box) and the approximate location of
the probes used for deletion analysis. Probes for loci D22S75 (N25)
and D22S66 (160b) lie within the DGCR. Cos 82 and pH17, the
control probes, map to the distal long arm of chromosome 22.
494 GOLDMUNTZ ET AL. JACC Vol. 32, No. 2
22q11 DELETIONS IN CARDIAC PATIENTS August 1998:492–8
Deletion frequency and associated vascular anomalies.
The relationship between 22q11 deletions and associated
vascular anomalies was evaluated in the subset of patients with
the highest deletion frequencies (IAA, TA, TOF and PMVSD).
For the purpose of these analyses, associated vascular anom-
alies included right aortic arch, cervical aortic arch, aberrant
right or left subclavian artery, aorticopulmonary collaterals, or
absent or discontinuous branch pulmonary arteries. Three
comparisons were designed to assess the relationship between
deletion status and associated vascular anomalies. Patients
without any associated vascular anomaly (that is, patients with
a normal left aortic arch) were compared to those with any
type of arch or vessel anomaly (Table 2, Comparison I).
Patients with at least one vascular anomaly were significantly
more likely to have a deletion of chromosome 22q11 than were
patients without any vascular anomaly (odds ratio 5 4.4, 95%
CI 2.0 to 9.9).
To determine whether deletion status is associated with
arch sidedness in the absence of other vessel anomalies,
patients with a right aortic arch and mirror image branching
were compared to patients with a left aortic arch and normal
branching pattern (Table 2, Comparison II). Deletions were
significantly more common in patients with a right aortic arch
than a left aortic arch (OR 5 3.1, 95% CI 1.2 to 8.3).
The relationship between deletion status and vessel anom-
alies, ignoring arch sidedness, was also assessed (Table 2,
Comparison III). Patients with either a normal left aortic arch
or right aortic arch and mirror image branching pattern were
compared to those with either a left or right aortic arch and
additional vessel anomalies. Deletions were significantly more
common in patients with an additional vessel anomaly than in
those without such abnormalities (odds ratio 5 4.2, 95% CI 1.8
to 9.6).
These analyses were repeated in the subgroup of patients
with TOF, the largest subgroup sharing the same primary
diagnosis. The results were not markedly different from those
described above (Table 2). However, none of the comparisons
was statistically significant in this subgroup of patients (that is,
the 95% confidence interval for the odds ratio included unity).
The relatively small number of patients with IAA, TA and
PMVSD precluded meaningful analyses of these subgroups.
Multiple logistic regression analyses. Multiple logistic re-
gression analyses were undertaken in an attempt to determine
whether the association between deletion status and associated
vascular anomalies was independent of the association be-
tween deletion status and the primary cardiac diagnosis. These
analyses were restricted to patients with a primary diagnosis of
IAA, TA, TOF or PMVSD, and patients were classified into
four, nonoverlapping groups on the basis of arch sidedness and
the presence/absence of at least one vessel abnormality: nor-
mal left aortic arch, right aortic arch with mirror image
branching, left aortic arch with at least one vessel abnormality
and right aortic arch with at least one vessel abnormality.
The logistic regression model that included both the pri-
mary and secondary diagnoses as predictor variables provided
a significantly better fit to these data than did either the model
which included only the primary cardiac diagnosis (chi-square
test with three dummy variables 5 22.0, p 5 0.00006), or the
model which included only the secondary diagnosis (chi-square
test with three dummy variables 5 17.0, p 5 0.0007) (Appendix
I). These results indicate that both the primary and secondary
cardiac diagnoses are independently related to deletion status.
The logistic regression equation for the model, which
included both primary and secondary cardiac diagnoses, was
used to predict the proportion of patients with specific combi-
nations of primary and secondary diagnoses who are expected
to have a deletion of chromosome 22q11 (Table 3). It can be
seen from Table 3 that, within each primary diagnosis category,
the expected proportion of patients with a deletion of chromo-
some 22q11 increased in the presence of the secondary diag-
nosis.
Table 2. Association Between Secondary Cardiac Diagnoses and Deletions of Chromosome 22q11 in Patients With TOF, TA, IAA or
PMVSD (n 5 185), and in Patients With TOF Only (n 5 126)
TOF, TA, IAA and PMVSD TOF only
Deleted (%) Nondeleted OR (95% CI)* Deleted Nondeleted OR (95% CI)*
Comparison I
Left aortic arch with normal branching 14 (12.8) 95 4.4 8 (10.8) 66 2.5
Any arch anomaly† 30 (39.5) 46 (2.0–9.9) 12 (23.1) 40 (0.8–7.6)
Comparison II
Left aortic arch with normal branching 14 (12.8) 95 3.1 8 (10.8) 66 2.2
Right aortic arch with mirror image branching 12 (31.6) 26 (1.2–8.3) 6 (21.4) 22 (0.6–8.3)
Comparison III
Left aortic arch with normal branching or right
aortic arch with mirror image branching
26 (17.7) 121 4.2 14 (13.7) 88 2.1
Any vessel anomaly‡ 18 (47.4) 20 (1.8–9.6) 6 (25.0) 18 (0.6–6.8)
*Exact confidence limits calculated using Epi Info, version 6.03. If the 95% confidence interval includes 1.0, the association is not statistically significant at p , 0.05.
If the 95% confidence interval excludes 1.0, the association is statistically significant at p , 0.05. †Includes right aortic arch, cervical aortic arch, aberrant right or left
subclavian artery, anteroposterior collateral and pulmonary artery anomalies. ‡Includes cervical aortic arch, aberrant right or left subclavian artery, AP collateral and
pulmonary artery anomalies. OR 5 odds ratio.
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Discussion
Deletion frequency and primary cardiac diagnosis. This
analysis was designed to determine the frequency of 22q11
deletions in cardiac patients based on their primary cardiac
diagnoses and associated vascular features. These findings may
assist the clinician in deciding which patients warrant further
genetic and clinical evaluation for the 22q11 deletion syn-
drome. This study analyzes the largest sample of patients
ascertained solely on the basis of cardiac status reported to
date. At the present time, the deletion frequencies reported in
this study serve as the best estimate of the frequency in patients
with the specific cardiac diagnoses. However, this report is not
a population-based study and the reported deletion frequency
may not represent the absolute prevalence of the deletion in
the patient population with conotruncal congenital heart dis-
ease.
Deletions of 22q11 were detected in 17.9% of the 251
patients ascertained with one of seven conotruncal defects:
IAA, TA, TOF, PMVSD, TGA, DORV and DOLV. Thus, this
study confirms that 22q11 deletions are important in the
etiology of conotruncal defects. The deletion frequency varied
with the primary diagnosis and was highest in patients with
IAA and TA (50.0% and 34.5%, respectively). These findings
are consistent with the clinical report by Van Mierop and
Kutsche (8). In our sample, 15.9% of patients with TOF have
a deletion, which is in agreement with other studies reporting
that 8 to 23% of TOF patients have a 22q11 deletion (11–13).
Our results indicate that deletions of 22q11 are as common in
patients with TOF/pulmonary atresia as those with TOF/
pulmonary stenosis or TOF/absent pulmonary valve, in con-
trast to another study suggesting that the deletion frequency is
higher in patients with TOF/absent pulmonary valve (18).
However, our sample size of 3 patients with TOF/absent
pulmonary valve is small.
Two of six patients with PMVSD had a deletion, a finding
that has not been previously reported and extends the spec-
trum of cardiac pathology associated with a 22q11 deletion. In
conjunction with previous reports, this finding suggests that
multiple abnormalities of the infundibular septum may occur
in association with the 22q11 deletion syndrome. The reported
abnormalities of the infundibular septum include anterior
malalignment (as seen in TOF), posterior malalignment (as
seen in isolation or in conjunction with IAA) and infundibular
hypoplasia (as seen in TOF) (19,20).
Only one of the 20 patients with DORV in this study had a
22q11 deletion. Takahashi and colleagues (12) reported that
none of eight patients with DORV had a deletion. These
reports together suggest that 22q11 deletions are relatively
infrequent in this subgroup. The only patient in the present
study with DORV and a deletion had a subaortic ventricular
septal defect, right aortic arch and isolated left pulmonary
artery. This lesion is reminiscent of TOF with multiple arch
anomalies and may explain why this subject was the only
DORV patient with a deletion. Given the anatomic variability
within the category of DORV, a small subgroup of these
patients may have a 22q11 deletion. Hence, further investiga-
tion of a larger sample of patients with DORV with detailed
anatomic description is warranted.
In the present study, none of the 45 patients with either d-
or l-TGA were found to have a 22q11 deletion using the
commercially available probe N25 (D22S75). Our results are
similar to those reported in a smaller study (n 5 16) by
Takahashi and colleagues (12). In contrast, three patients with
TGA and a ventricular septal defect have been reported in
association with unbalanced translocations resulting in dele-
tion of this region (21). In addition, Melchionda and colleagues
(22) demonstrated a deletion at locus D22S134 (KI-182/
HP500) within the commonly deleted region in 12.5% (4 of 32)
of patients with TGA. The differences in these studies may
reflect the small sample size or unappreciated differences in
the patient populations. Based on the published data, it
appears that the proportion of TGA patients with a 22q11
deletion is likely to be relatively low.
Deletion frequency and associated vascular abnormalities.
Our data indicate that the deletion frequency is higher in
patients with the secondary diagnosis of any arch or vessel
anomaly as compared to those with a normal left aortic arch.
We further investigated whether arch sidedness or the pres-
ence of other vessel anomalies was associated with deletion
status. Patients with a right aortic arch were more likely to have
a chromosome 22q11 deletion than patients with a normal left
aortic arch. The frequency of deletions was also significantly
higher in patients with a vessel anomaly regardless of arch
sidedness.
Multiple logistic regression analyses indicated that the
association between secondary cardiac abnormalities (arch
and/or vessel abnormalities) and deletions of chromosome
22q11 are independent of the association between this deletion
and the primary cardiac abnormality. Based on the full logistic
regression model, the probability of having a deletion varied
with the primary diagnosis, and within each primary diagnosis
category, the probability of having a deletion varied with the
secondary diagnosis. Since the logistic regression model is
based on a relatively small sample of patients, the predicted
probabilities of having a deletion of chromosome 22q11 are
likely to be imprecise and should not be used for genetic
counseling or patient management. However, the observed
association between arch/vessel anomalies and chromosome
Table 3. Predicted Probability of Having a Deletion of Chromosome
22q11 Based on the Full Logistic Regression Model
Primary
Diagnosis
Secondary Diagnosis*
LN RM LA RA
TOF 0.06 0.24 0.31 0.40
TA 0.16 0.48 0.56 0.66
PMVSD 0.22 0.56 0.64 0.73
IAA 0.36 0.72 0.78 0.85
*LN 5 left aortic arch with normal branching; RM 5 right aortic arch with
mirror image branching; LA 5 left aortic arch with a vessel abnormality(ies);
RA 5 right aortic arch with a vessel abnormality(ies).
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22q11 deletions provide insight into the pathogenesis of the
cardiac anomalies seen in the 22q11 deletion syndrome.
Our findings are similar to those reported by Momma and
colleagues (19,23) who compared the additional cardiac fea-
tures in patients with TOF (PS or PA) with a deletion to those
without a deletion. In both studies, patients with a deletion
were found to have an anomaly of the pulmonary arteries,
aortic arch or its major branches more frequently than patients
without the deletion.
Deletion screening and noncardiac features. This investi-
gation evaluates the likelihood of identifying the patient with a
22q11 deletion based solely on cardiac anatomy. Patients with
22q11 deletions may present with other important findings
such as palatal abnormalities, craniofacial dysmorphia, absent
thymus, hypocalcemia, speech and learning difficulties or neu-
ropsychological disorders (24). Patients with conotruncal car-
diac disease should be examined for the presence of noncar-
diac abnormalities which may assist in identifying those
patients who are likely to have a deletion. However, subtle
noncardiac features may not be apparent in infancy when the
vast majority of patients are diagnosed with congenital heart
disease. For example, several investigators have reported clas-
sifying a patient as nonsyndromic only to be surprised at the
finding of a deletion (11,13,14). In these studies, reexamination
of the patient at an older age revealed features consistent with
VCFS that were not appreciated on earlier examinations. In
contrast, patients may have features suggestive of VCFS
without a 22q11 deletion. For example, in our original report,
5 of 12 patients without a 22q11 deletion had additional
findings. Likewise, in the report by Webber et al. (14), many
patients were classified as having features of VCFS but were
not found to have the deletion. Some of the classic features are
age-dependent while others, such as facial dysmorphia, are
more subjective. Therefore, the present study design did not
consider findings other than cardiac anatomy in the analysis,
and demonstrates that cardiovascular anatomy alone can be
used to predict which patients are more likely to have a
deletion. Additional studies are in progress to assess how
inclusion of objective diagnoses such as thymic aplasia, palatal
abnormalities or symptomatic hypocalcemia in the neonate
alters the probability of finding a deletion. Only a longitudinal
study that follows the infant through school age and perhaps
into adulthood will identify the presence of all potential
noncardiac features (such as learning disabilities, hypernasal
speech, neuropsychiatric disorders or facial dysmorphia) and
determine whether any patients with truly isolated conotruncal
defects have a 22q11 deletion. In the future, these analyses may
enable us to better identify which cardiac patients should be
tested for the deletion.
Conclusions. In summary, this study demonstrates that
cardiac patients with IAA, TA and TOF frequently have a
22q11 deletion. Despite the paucity of predictive outcome
information, we believe that it is important to recognize the
patient with a 22q11 deletion at an early age to allow for the
diagnosis and treatment of associated medical problems such
as feeding disorders, hypocalcemia, immune deficiencies, neu-
rodevelopmental difficulties, palatal abnormalities and speech
problems. In addition, knowledge of the deletion status will
influence the genetic counseling provided to the family and
other family members. Thus, at this time, we recommend that
all newly diagnosed infants with IAA, TA and TOF be
evaluated for the presence of a 22q11 deletion. Deletion
testing of school age children with these cardiac defects is
recommended in the presence of additional features of VCFS.
Patients with a PMVSD should also be considered for deletion
screening. Our data suggest that deletions in patients with
TGA and DORV are infrequent in contrast to other reports
(21,22). Therefore, until additional studies are completed, we
recommend testing patients with TGA or DORV for a dele-
tion when other features of VCFS are diagnosed. The presence
of extracardiac features commonly seen in the 22q11 deletion
syndrome should prompt a genetic evaluation and molecular-
cytogenetic studies in any cardiac patient. Finally, studies
integrating noncardiac features into the regression analysis of
deletion probability are underway and may help to develop
appropriate guidelines for deletion screening. Additional stud-
ies looking at the cost effectiveness and long-term benefit of
deletion testing may also be helpful in the development of
Table 4. Summary of Model Fitting Using Logistic Regression Analysis
Model Predictor Variables -2ln(L) df D-2ln(L) Ddf p value
I Primary and secondary diagnosis 166.543 6 — — —
II Primary diagnosis 188.537 3 22.0 3 0.00006*
III Secondary diagnosis 183.544 3 17.0 3 0.0007†
*Model II versus model I. †Model III versus model I.
Table 5. Odds Ratios and 95% Confidence Intervals Estimated
From the Full Logistic Regression Model
Dummy Variables Odds Ratio 95% Confidence Interval
Primary diagnosis*
P1 2.8 1.06–7.52
P2 4.0 0.60–26.78
P3 8.1 2.74–23.99
Secondary diagnosis†
S1 4.6 1.72–12.25
S2 6.3 2.19–18.27
S3 9.6 2.57–36.19
*TOF: P1 5 P2 5 P3 5 0; TA: P1 5 1, P2 5 P3 5 0; PMVSD: P2 5 1, P1 5
P3 5 0; IAA: P3 5 1, P1 5 P2 5 0. †Left aortic arch with normal branching: S1 5
S2 5 S3 5 0; right aortic arch with mirror image branching: S1 5 1, S2 5 S3 5
0; left aortic arch with a vessel abnormality(ies): S2 5 1, S1 5 S3 5 0; right aortic
arch with a vessel abnormality(ies): S3 5 1, S1 5 S2 5 0.
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guidelines for testing, as will the long-term follow-up and
evaluation of patients with conotruncal malformations.
The authors wish to thank the members of the Divisions of Cardiology and
Cardiothoracic Surgery as well as the Staff of the Cardiac Intensive Care Unit at
The Children’s Hospital of Philadelphia for assistance with patient recruitment,
Yvonne Tatsumura for technical assistance, Colleen Oates for secretarial
assistance; and ONCOR, Gaithersburg, MD for providing the N25 and pH17
probes.
Appendix
Logistic regression analyses were used to assess the association be-
tween deletion status and both primary and secondary cardiac diag-
noses. Three models were fit to the data. The full analysis model
included 6 variables: three dummy variables which defined the four
primary diagnoses (i.e., IAA, TA, VSD and TOF), and 3 dummy
variables which defined the four secondary diagnoses (i.e., none, right
aortic arch with mirror image branching, left aortic arch with at least
one vessel abnormality, and right aortic arch with at least one vessel
abnormality). Two reduced models, one including only the three
dummy variables defining the primary diagnosis, and one including
only the three dummy variables defining the secondary diagnosis, were
also fit to the data. The fit of the reduced models to the data, relative
to the fit of the full model was evaluated by use of the likelihood ratio
test—that is, twice the difference between the log likelihood of the full
and reduced models. This test is distributed approximately as a x2, with
the degrees of freedom determined by the difference in the number of
parameters estimated by the two models.
The model which included both the primary and secondary diag-
noses provided a significantly better fit to these data than either of the
reduced models (Table 4), indicating that both primary and secondary
cardiac features are related to a patients deletion status. The odds
ratios and associated 95% confidence intervals obtained under the full
model are provided in Table 5.
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